Valsartan and Hydrochlorothiazide Tablets
Belongs to Category:
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
Product Description
Approval Number:
H20213285
Indications:
It is used for treating mild to moderate essential hypertension when valsartan alone cannot adequately control blood pressure. This product is not suitable for the initial treatment of hypertension.
Administration:
Each tablet of this product contains 80 mg of olmesartan and 12.5 mg of hydrochlorothiazide. When valsartan monotherapy fails to satisfactorily control blood pressure, hydrochlorothiazide 25 mg once-daily can be added to control blood pressure or prevent hypokalemia. The maximum dosage (containing 80 mg of valsartan and 12.5 mg of hydrochlorothiazide) is taken once a day, and the effect can be seen within 2-4 weeks.
Specifications:
80mg/12.5mg × 10/14/28 tablets
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
The main products cover cardiovascular diseases, diabetic complications, anti-tumor, calcium supplementation, digestive system, respiratory system, and orthopedics.
Related Products
Online Message
We will contact you within one business day. Please pay attention to your email.
Email: marcos.yuan@wangao.com.cn
Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province
Mobile Version QR Code
WeChat Official Account
Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.